Biomedical and Environmental Sciences

1

Report on Cardiovascular Health and Diseases in China 2023: An Updated Summary (30 day view times: 66)

National Center for Cardiovascular Diseases The Writing Committee of the Report on Cardiovascular Health and Diseases in China

2024, 37(9): 949-992. doi: 10.3967/bes2024.162

HTML Full Text PDF 2831KB

Since 1990, China has made considerable progress in resolving the problem of “treatment difficulty” of cardiovascular diseases (CVD). The prevalent unhealthy lifestyle among Chinese residents has exposed a massive proportion of the population to CVD risk factors, and this situation is further worsened due to the accelerated aging population in China. CVD remains one of the greatest threats to the health of Chinese residents. In terms of the proportions of disease mortality among urban and rural residents in China, CVD has persistently ranked first. In 2021, CVD accounted for 48.98% and 47.35% of deaths in rural and urban areas, respectively. Two out of every five deaths can be attributed to CVD. To implement a national policy “focusing on the primary health institute and emphasizing prevention” and truly achieve a shift of CVD prevention and treatment from hospitals to communities, the National Center for Cardiovascular Diseases has organized experts from relevant fields across China to compile the “Report on Cardiovascular Health and Diseases in China” annually since 2005. The 2024 report is established based on representative, published, and high-quality big-data research results from cross-sectional and cohort population epidemiological surveys, randomized controlled clinical trials, large sample registry studies, and typical community prevention and treatment cases, along with data from some projects undertaken by the National Center for Cardiovascular Diseases. These firsthand data not only enrich the content of the current report but also provide a more timely and comprehensive reflection of the status of CVD prevention and treatment in China.

2

Interpretation of Annual Report on Cardiovascular Health and Diseases in China 2024 (30 day view times: 31)

Mingbo Liu, Xinye He, Xiaohong Yang, Zengwu Wang

2025, 38(8): 893-917. doi: 10.3967/bes2025.099

HTML Full Text PDF 5971KB

Cardiovascular diseases (CVD) and their risk factors are exerting an increasingly significant impact on public health, and the incidence rate of CVD continues to rise. This article provides an interpretation of essentials from the newly published Annual Report on Cardiovascular Health and Diseases in China (2024), aiming to offer scientific evidence for CVD prevention, treatment, and the formulation of relevant policies.

3

Joint Associations of Sarcopenia and Social Isolation with Mortality: Two Prospective Cohort Studies across Different Cultural Contexts (30 day view times: 28)

Juanjuan Li, Zhe Zhang, Jijuan Zhang, Yuxiang Wang, Hancheng Yu, Gang Liu, An Pan, Yunfei Liao, Tingting Geng

2026, 39(1): 3-14. doi: 10.3967/bes2025.113

HTML Full Text PDF 2085KB

Objective This study aims to investigate the joint associations of sarcopenia and social isolation with mortality risk. Methods Using data from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) and the UK Biobank, sarcopenia was diagnosed according to European and Asian Working Groups for Sarcopenia criteria. Social isolation was assessed using standardized questionnaires, including questions on solitude, frequency of social activities, contact with others, and marital status (for the CLHLS only). Results During the follow-up period, 8,249 deaths occurred in the CLHLS and 26,670 deaths in the UK Biobank groups. While no significant interaction was observed between sarcopenia and social isolation in predicting all-cause mortality in the CLHLS cohort, the association between social isolation and mortality was stronger among individuals with sarcopenia in the UK Biobank (P-interaction = 0.03, relative risk due to interaction: 0.23, 95% confidence interval [CI]: 0.06–0.41). Further joint analyses showed that participants with sarcopenia and high levels of social isolation had the highest mortality risk (hazard ration [HR]: 1.99; 95% CI: [1.74–2.28] in the CLHLS and 1.69 [1.55–1.85] in the UK Biobank) compared to those without either condition. Conclusion The combination of social isolation and sarcopenia synergistically increases the risk of mortality in middle-aged and older adults across diverse populations.

4

Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary (30 day view times: 24)

The Writing Committee of the Report on Cardiovascular Health and Diseases in China

2023, 36(8): 669-701. doi: 10.3967/bes2023.106

HTML Full Text PDF 1561KB

In the past 30 years, the accessibility and quality index of medical care have made remarkable progress in China, ranking the first among middle-income countries. Many cardiovascular technologies are at or near the world's leading level, and significant progress has been achieved in China solving the problem of “treatment difficulty” of cardiovascular diseases (CVD). However, due to the prevalence of unhealthy lifestyles among Chinese residents, a huge population with CVD risk factors, accelerated population aging, and other reasons, the incidence and mortality rate of CVD are still increasing, and the turning point of the decline in disease burden has not appeared yet in China. In terms of proportions of disease mortality among urban and rural residents, CVD still ranks the first. In 2020, CVD accounted for 48.00% and 45.86% of the causes of death in rural and urban areas, respectively; two out of every five deaths were due to CVD. It is estimated that the number of current CVD patients in China is around 330 million, including 13 million stroke, 11.39 million coronary heart disease, 8.9 million heart failure, 5 million pulmonary heart disease, 4.87 million atrial fibrillation, 2.5 million rheumatic heart disease, 2 million congenital heart disease, 45.3 million peripheral artery disease, and 245 million hypertension cases. China has entered a new stage of transformation from high-speed development to high-quality development, and the prevention and control of CVD in China should also shift from previous emphasis on scale growth to strategies focusing more on strategic and key technological development in order to curb the trend of increasing incidence and mortality rates of CVD.

5

Associations between Premature Menopause and Cardiovascular-Kidney-Metabolic Syndrome: A Prospective Cohort Study from the UK Biobank (30 day view times: 20)

Ming Jin, Zeping Yang, Ziyi Zhang, Zhexin Luo, Ninghao Huang, Tao Huang, Xiaojing Liu, Nan Li

2026, 39(1): 105-110. doi: 10.3967/bes2026.002

HTML Full Text PDF 1495KB

6

Cardiac Organoids: Emerging Tools for Investigating Environmental Roles in Cardiomyopathy Pathogenesis and Therapeutic Development (30 day view times: 18)

Yaoyao Xu, Zhimin Wang

2026, 39(1): 82-104. doi: 10.3967/bes2025.104

HTML Full Text PDF 2589KB

Human cardiac organoids have revolutionized the study of cardiac development, disease modeling, drug discovery, and regenerative therapies. This review systematically discusses strategies and progress in the construction of cardiac organoids, categorizing them into three main types: cardiac spheroids, self-organizing/assembloid organoids, and organoid-on-a-chip systems. This review uniquely integrates the advances in vascularization, organ-on-chip design, and environmental cardiotoxicity modeling within cardiac organoid platforms, offering a critical synthesis that is absent in the literature. In the context of escalating environmental threats to cardiovascular health, there is an urgent need for physiologically relevant models to accurately identify cardiac toxicants and elucidate their underlying mechanisms of action. This review highlights advances in cardiac organoid applications for disease modeling—including congenital heart defects and acquired cardiovascular diseases—drug development, toxicity screening, and the study of environmentally induced cardiovascular pathogenesis. In addition, it critically examines ongoing challenges and underscores opportunities brought by bioengineering approaches. Finally, we propose future directions for developing standardized cardiac organoid platforms with clinical predictability, aiming to expand the utility of this technology across broader research applications.

7

Chinese Expert Consensus on the Application of Metagenomic Sequencing Technology in Ocular Infectious Diseases: A Delphi Method (30 day view times: 18)

Songtao Xu, Zhuyun Qian, Yong Tao

2025, 38(12): 1550-1557. doi: 10.3967/bes2025.156

HTML Full Text PDF 1289KB

8

Tackling Adult Obesity in China: A Time for Action (30 day view times: 18)

Xiao Zhang, Limin Wang

2025, 38(12): 1466-1469. doi: 10.3967/bes2025.149

HTML Full Text PDF 1266KB

9

Association of Frailty with Mortality and Incident Cardiovascular Disease: The Role of Metabolic Status (30 day view times: 17)

Youjing Wang, Tingting Geng, Ku Xun, Jinchi Xie, Dan Xue, Yuxiang Wang, Gang Liu, An Pan

2025, 38(12): 1490-1501. doi: 10.3967/bes2025.154

HTML Full Text PDF 1957KB

Objective To identify whether metabolic status mediates the associations between frailty and mortality and incident cardiovascular disease (CVD), and to assess of interactive or joint relationships between frailty and metabolic status on these outcomes. Methods In this prospective cohort study of 456,445 UK Biobank participants, frailty was assessed using five phenotype criteria. Metabolic status was scored (0–4) based on central obesity, hypertension, hyperglycemia, and dyslipidemia. Multivariable-adjusted Cox regression models were used to assess the associations between frailty and mortality and incident CVD. Results During a median follow-up of 13.8 years for mortality and 13.6 years for CVD, 30,907 deaths (7,467 CVD-related) and 37,115 incident CVD cases occurred. Frailty was associated with higher risks of all-cause mortality (hazard ratio [HR], 2.41; 95% confidence interval [CI], 2.31–2.51), CVD mortality (HR, 2.64; 95% CI, 2.43–2.87), and incident CVD (HR, 1.83; 95% CI, 1.75–1.91), compared with non-frail individuals. Metabolic status mediated 8.7%, 16.1%, and 16.4% of these associations, respectively. Frailty and metabolic status interacted multiplicatively for all-cause mortality (P-value for interaction < 0.001) and additively for CVD mortality [relative excess risk due to interaction (RERI), 1.78; 95% CI, 0.88–2.68] and incident CVD (RERI, 0.60; 95% CI, 0.33–0.86). Joint exposure to frailty and three to four metabolic disorders conferred 3.34-, 6.32-, and 3.30-fold risks of all-cause mortality, CVD mortality, and incident CVD, respectively, compared with metabolically healthy non-frail individuals. Conclusion This study highlights the need for integrated management strategies targeting both frailty and metabolic conditions to mitigate cardiovascular and mortality risks.

10

Progress on Wastewater-based Epidemiology in China: Implementation Challenges and Opportunities in Public Health (30 day view times: 17)

Qiuda Zheng, Xialu Lin, Yingsheng He, Zhe Wang, Peng Du, Xiqing Li, Yuan Ren, Degao Wang, Luhong Wen, Zeyang Zhao, Jianfa Gao, Phong K. Thai

2025, 38(11): 1354-1358. doi: 10.3967/bes2025.133

HTML Full Text PDF 1425KB

Wastewater-based epidemiology has emerged as a transformative surveillance tool for estimating substance consumption and monitoring disease prevalence, particularly during the COVID-19 pandemic. It enables the population-level monitoring of illicit drug use, pathogen prevalence, and environmental pollutant exposure. In this perspective, we summarize the key challenges specific to the Chinese context: (1) Sampling inconsistencies, necessitating standardized 24-hour composite protocols with high-frequency autosamplers (≤ 15 min/event) to improve the representativeness of samples; (2) Biomarker validation, requiring rigorous assessment of excretion profiles and in-sewer stability; (3) Analytical method disparities, demanding inter-laboratory proficiency testing and the development of automated pretreatment instruments; (4) Catchment population dynamics, reducing estimation uncertainties through mobile phone data, flow-based models, or hydrochemical parameters; and (5) Ethical and data management concerns, including privacy risks for small communities, mitigated through data de-identification and tiered reporting platforms. To address these challenges, we propose an integrated framework that features adaptive sampling networks, multi-scale wastewater sample banks, biomarker databases with multidimensional metadata, and intelligent data dashboards. In summary, wastewater-based epidemiology offers unparalleled scalability for equitable health surveillance and can improve the health of the entire population by providing timely and objective information to guide the development of targeted policies.

11

Health Determinants in Association with Cancer Mortality from a Health Ecological Perspective (30 day view times: 17)

Chenran Wang, Zilin Luo, Jiaxin Xie, Xiaolu Chen, Yadi Zheng, Zeming Guo, Xiaoyue Shi, Xinyue Zhu, Wei Cao, Fei Wang, Xuesi Dong, Ni Li

2025, 38(12): 1470-1481. doi: 10.3967/bes2025.152

HTML Full Text PDF 1955KB

Objective To explore the health determinants of all-cancer mortality from a health-ecological perspective. Methods Using the health-ecological model, we identified 15 health determinants across five domains: personal innate, behavioral, interpersonal network, socioeconomic, and macroenvironmental characteristics. Data on cancer outcomes and health determinants from 185 countries, classified using the Human Development Index (HDI), were extracted from GLOBOCAN 2022, the World Health Organization Global Health Observatory, the Global Burden of Disease Study 2021, the United Nations, and the World Bank. A multivariate linear regression model was used to estimate the association between health determinants and cancer outcomes. Results A total of 153 countries with complete information on cancer outcomes and health determinants were enrolled in the study. A higher all-cancer age-standardized mortality rate (ASMR) was associated with current tobacco use, alcohol consumption, obesity, agricultural employment, and lag-distributed income. In women aged 15–49 years, being married or in a union was associated with a lower ASMR. Early-onset ASMR was positively associated with agricultural employment, lag-distributed income, and unsafe sanitation. Notable sex differences were observed, although tobacco use and obesity were identified as risk factors in both sexes. Conclusion We underscore the crucial need to incorporate cross-sectoral interventions within a resilient healthcare system to effectively mitigate the cancer mortality burden.

12

The Association between Exposure to Second-Hand Smoke and Disease in the Chinese Population: A Systematic Review and Meta-Analysis (30 day view times: 16)

WANG Yu Tong, HU Kui Ru, ZHAO Jian, AI Fei Ling, SHI Yu Lin, WANG Xue Wei, YANG Wen Yi, WANG Jing Xin, AI Li Mei, WAN Xia

2023, 36(1): 24-37. doi: 10.3967/bes2023.003

HTML Full Text PDF 2004KB

Objective To analyze the association between exposure to second-hand smoke (SHS) and 23 diseases, categorized into four classifications, among the Chinese population. Methods We searched the literature up to June 30, 2021, and eligible studies were identified according to the PECOS format: Participants and Competitors (Chinese population), Exposure (SHS), Outcomes (Disease or Death), and Study design (Case-control or Cohort). Results In total, 53 studies were selected. The odds ratio (OR) for all types of cancer was 1.79 (1.56–2.05), and for individual cancers was 1.92 (1.42–2.59) for lung cancer, 1.57 (1.40–1.76) for breast cancer, 1.52 (1.12–2.05) for bladder cancer, and 1.37 (1.08–1.73) for liver cancer. The OR for circulatory system diseases was 1.92 (1.29–2.85), with a value of 2.29 (1.26–4.159) for stroke. The OR of respiratory system diseases was 1.76 (1.13–2.74), with a value of 1.82 (1.07–3.11) for childhood asthma. The original ORs were also shown for other diseases. Subgroup analyses were performed for lung and breast cancer. The ORs varied according to time period and were significant during exposure in the household; For lung cancer, the OR was significant in women. Conclusion The effect of SHS exposure in China was similar to that in Western countries, but its definition and characterization require further clarification. Studies on the association between SHS exposure and certain diseases with high incidence rates are insufficient.

13

Long-term Cumulative Depressive Symptoms and Incident Cardiovascular Disease in Middle-aged and Older Population: Two Cohort Studies (30 day view times: 16)

Fangfei You, Yining Gao, Wenfang Zhong, Zhihao Li, Jian Gao, Dong Shen, Xiaomeng Wang, Weiqi Song, Qi Fu, Haoyu Yan, Jiahao Xie, Huan Chen, Hao Yan, Chen Mao

2026, 39(1): 15-25. doi: 10.3967/bes2025.165

HTML Full Text PDF 1583KB

Objective Elevated depressive symptoms are well-documented among geriatric adults with cardiovascular disease (CVD); however, few studies have accounted for long-term cumulative depressive symptom exposure. This study determined the relationship between cumulative depressive symptoms and CVD. Methods Individual participant data were obtained from the China Health and Retirement Longitudinal Study (CHARLS) and Health and Retirement Study (HRS). Eligible participants had access to assessment information on depressive symptoms and had no history of CVD at baseline. Long-term cumulative depressive symptoms were estimated by calculating the area under the curve based on the Center for Epidemiological Studies Depression Scale. Results Herein, 8,861 participants from CHARLS (mean age: 58.58 years; male: 48.6%) and 7,284 from HRS (60.94 years; 35.0%) were enrolled. The median follow-up period was 5 years for the CHARLS and 10 years for the HRS. Compared with the first quartile of cumulative depressive symptoms, the HRs (95% CI) in the fourth quartile were 1.73 (1.48, 2.02) for predicting CVD (P < 0.001), 1.83 (1.52, 2.19) for heart disease (P < 0.001), 1.53 (95% CI: 1.17, 1.99) for stroke (P = 0.002) in CHARLS. For HRS, the HRs (95% CI) were 1.41 (95% CI: 1.27, 1.57; P < 0.001), 1.42 (95% CI: 1.26, 1.59; P < 0.001), and 1.30 (95% CI: 1.06, 1.58; P = 0.010) respectively. Strong dose-response relationships were observed, with similar results for the two cohorts. Conclusion Long-term cumulative depressive symptoms were significantly associated with incident CVD in middle-aged and older adults, providing insights into controlling long-term depressive symptoms to improve this cohort’s health.

14

Impact of PCSK9 Inhibitor Recaticimab on Hyperlipidemia and Plasma Glucose: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study (30 day view times: 16)

Ye Hu, Chen Chen, Xiaohui He, Shuyu Zhang, Xuhong Wang

2025, 38(10): 1246-1254. doi: 10.3967/bes2025.123

HTML Full Text PDF 1423KB

Objective Recaticimab (SHR-1209) significantly reduces low-density lipoprotein cholesterol levels. However, its effect on glucose metabolism remains unclear. This study aimed to evaluate its effect on glycemic parameters in a Chinese population. Methods Recaticimab versus placebo was administered in a 5:1 ratio to 110 hyperlipidemia patients who were followed up for 24 weeks. Glycated hemoglobin (HbA1c) levels were measured at baseline every 12 weeks. Fasting plasma glucose (FPG) levels were measured at baseline at week 1, 3, 5, 8, 12, 16, 20, and 24. Repeated-measures mixed-effects models were used to determine the longitudinal association between reacticimab and FPG and HbA1c levels. Results Among the 81 participants with normal glucose metabolism, HbA1c levels significantly decreased (F = 4.568, P = 0.036). In the 29 participants with abnormal glucose metabolism, a significant time effect was observed for FPG levels (F = 2.492, P = 0.016). For participants with normal and abnormal glucose metabolism, no significant group × time interaction effects on FPG or HbA1c levels were identified. Conclusion Recaticimab showed no adverse glycemic effects in participants with normal or abnormal glucose metabolism, indicating its safety in patients with or without diabetes.

15

Cardiovascular Health and Disease Report in China: Two Decades of Progress (30 day view times: 16)

Shuyao Su, Fangchao Liu

2025, 38(8): 891-892. doi: 10.3967/bes2025.098

HTML Full Text PDF 1191KB

16

The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis (30 day view times: 15)

Mengqing Zhang, Chu Lin, Xiaoling Cai, Ruoyang Jiao, Shuzhen Bai, Zonglin Li, Suiyuan Hu, Fang Lyu, Wenjia Yang, Linong Ji

2024, 37(6): 607-616. doi: 10.3967/bes2024.067

HTML Full Text PDF 2562KB

Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on asthma, which is often comorbid with type 2 diabetes mellitus (T2DM) and obesity. Therefore, we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1 (GLP-1) receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity. Methods PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials, and Clinicaltrial.gov were systematically searched from inception to July 2023. Randomized controlled trials (RCTs) of GLP-1 receptor-based agonists (GLP-1RA, GLP-1 based dual and triple receptor agonist) with reports of asthma events were included. Outcomes were computed as risk ratios (RR) using a fixed-effects model. Results Overall, 39 RCTs with a total of 85,755 participants were included. Compared to non-GLP-1 receptor-based agonist users, a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments, although the difference was not statistically significant [RR = 0.91, 95% confidence interval (CI): 0.68 to 1.24]. Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users (RR = 0.65, 95% CI: 0.43 to 0.99, P = 0.043). We also performed sensitivity analyses for participant characteristics, study design, drug structure, duration of action, and drug subtypes. However, no significant associations were observed. Conclusion Compared with non-users, a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments. Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma.

17

Disease Burden and Trends of COPD in the Asia-Pacific Region (1990–2019) and Predictions to 2034 (30 day view times: 15)

Jing Ma, Hong Mi

2025, 38(5): 557-570. doi: 10.3967/bes2025.040

HTML Full Text PDF 1528KB

Objective The Asia-Pacific region has a high chronic obstructive pulmonary disease (COPD) burden, but studies on its trends are limited. Using the Global Burden of Disease (GBD) 2019 data, we analyzed COPD trends in 36 countries and territories from 1990 to 2019 and predicted future incidence trends through 2034. Methods COPD data by age and sex from the GBD 2019 database were analyzed for incidence, prevalence, mortality, and disability-adjusted life years (DALY) rates from 1990 to 2019. Joinpoint regression identified significant annual trends, and age-standardized incidence rates were predicted through 2034 using age–period–cohort models. Results The incidence, prevalence, mortality, and disease burden of COPD have been decreasing, and the incidence rates will continue to decrease or remain stable until 2034 in most selected countries and territories, except for a few Southeastern Asian countries. The Lao People’s Democratic Republic and Vietnam are projected to experience an increase in COPD incidence from 165.3 per 100,000 in 2019 to 177 per 100,000 in 2034 and from 179.9 per 100,000 in 2019 to 192.5 per 100,000 in 2034, respectively. Older males had a higher incidence than any other sex or age group. The sex gap in incidence rates continues to widen, though it is smaller and less significant in the younger age group than in those in the older one. Conclusion COPD rates are expected to decline until 2034 but remain a health risk, especially in countries with rising rates. Urgent action on tobacco control, air pollution, and public education is needed.

18

Predictors of Short-term Relapse after Successful Smoking Cessation among Patients Attending Smoking Cessation Clinics in China, 2019–2021: A Retrospective Cohort Study (30 day view times: 15)

Li Xie, Shiwei Liu, Xinying Zeng, Lin Xiao

2025, 38(12): 1544-1549. doi: 10.3967/bes2025.148

HTML Full Text PDF 1264KB

The Chinese government promotes smoking cessation through smoking cessation clinics (SCCs). This study aimed to identify factors associated with relapse and provide evidence to inform interventions that reduce relapse risk. Participants were SCC patients aged ≥ 18 years who enrolled between June 2019 and December 2021, completed follow-up assessments at one and three months, and reported abstinence at one month. Short-term relapse was defined as self-reported smoking at the three-month follow-up. Treatments included counseling, first-line cessation medications, and traditional Chinese medicine (TCM). Logistic regression was used to identify factors associated with short-term relapse. Among 10,724 eligible SCC patients, 11.6% experienced short-term relapse. Factors positively associated with relapse included the number of previous quit attempts (1–5 attempts: OR = 1.422, 95% CI: 1.254–1.613, > 5 attempts: OR = 1.382, 95% CI: 1.057–1.808), high perceived difficulty in quitting (OR = 1.297, 95% CI: 1.061–1.586), and moderate (OR = 1.383, 95% CI: 1.174–1.629) or weak (OR = 1.517, 95% CI: 1.251–1.841) willingness to quit. Factors negatively associated with relapse included having a college degree or higher (OR = 0.796; 95% CI: 0.650–0.973), high confidence in quitting (OR = 0.786; 95% CI: 0.629–0.983), and use of TCM (OR = 0.276; 95% CI: 0.158–0.482). Enhancing self-efficacy in quitting appears crucial for preventing short-term relapse. The use of TCM may reduce relapse risk and warrants further investigation.

19

Excess Body Weight and Its Influence on Colonoscopy Adherence and Findings: Results from an Opportunistic Colorectal Cancer Screening Program in Chongqing (30 day view times: 14)

Xiaoyue Shi, Jia Du, Xuesi Dong, Zeming Guo, Jiaxin Xie, Zilin Luo, Xiaolu Chen, Chenran Wang, Yadi Zheng, Yan Zhang, Wei Cao, Fei Wang, Ni Li, Mei He

2025, 38(12): 1482-1489. doi: 10.3967/bes2025.153

HTML Full Text PDF 2006KB

Objective To examine the effect of excess body weight on adherence and lesion detection in colorectal cancer (CRC) screening. Methods A cross-sectional analysis was conducted within an opportunistic CRC screening program in Chongqing, which enrolled 43,797 adults aged 35–74 years between 2021 and 2022. A total of 42,279 participants were included in the final analysis, of whom 19,462 (46.0%) had excess body weight (BMI > 24.0 kg/m²). Colonoscopy adherence and detection were compared between normal and excess body weight group, and associated factors were examined. Results Of the 7,002 participants recommended for colonoscopy, 3,808 (54.4%) had excess body weight. Adherence was significantly lower in the excess weight group (6.6%) than in the normal weight group (10.7%, P < 0.001), and this trend was consistent across sex and age groups. The detection rates of advanced neoplasms (3.6% vs. 1.8%) and non-advanced adenomas (10.7% vs. 6.7%) were higher in the excess weight cohort, with a significant difference for any neoplasm (14.2% vs. 8.9%, P < 0.05). Differences in adherence- and detection-related factors were also observed between the groups. Conclusion Excess body weight was associated with lower colonoscopy adherence but higher neoplasm detection. These findings support the integration of weight management with targeted screening promotion to improve CRC prevention in this high-risk population.

20

Genomic Epidemiology of Foodborne bla_NDM-9Gene-Carrying Extensively Drug-Resistant (XDR) Salmonella enterica Serovar Indiana ST17 (30 day view times: 14)

Yujie Hu, Peiyuan Huang, Maosong Tian, Lei Zheng, Jun He, Bingbing Li, Jianyun Zhao, Séamus Fanning, Li Bai, Yinping Dong

2025, 38(12): 1558-1563. doi: 10.3967/bes2025.147

HTML Full Text PDF 1998KB

Most Download

ScholarOne Manuscripts Log In

Current Issue

Links